Skip to content

CorMedix CRMD Restricted Cash

Restricted Cash at other companies

Merck & Co. logo
Merck & Co.MRK
$71M-31.1%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$1.2M-67.6%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$1.73M+308%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$202M+153%
Baxter International logo
Baxter InternationalBAX
Medline, Inc.
 logo
Medline, Inc. MDLN

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's restricted cash?
CorMedix (CRMD) reported restricted cash of $656K in Q1 2026.
What is the long-term trend for CorMedix's restricted cash?
Over 5 years (2020 to 2025), CorMedix's restricted cash has grown at a 11.7% compound annual growth rate (CAGR), from $191.31K to $332K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.